The effect of magnesium and zinc co-supplementation in patients with coronary heart disease and type 2 diabetes mellitus

The effect of magnesium and zinc co-supplementation on metabolic profiles in patients with coronary heart disease and type 2 diabetes mellitus

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20130211012438N31

Enrollment

Registered

2019-05-11

Start date

2019-01-05

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

coronary heart disease and type 2 diabetes mellitus. Chronic ischemic heart disease, unspecified

Interventions

Intervention 1: Intervention group: a capsule containing150 mg zinc sulfate and 250 mg magnesium oxide once a day for 3 months. Intervention 2: Control group: 1000 mg Placebo capsule containing corn

Eligibility

Sex/Gender

All

Age

40 Years to 95 Years

Inclusion criteria

Inclusion criteria: patients with coronary disease on angiography ;patients with diabetes with American Diabetes Association; age 40 to 95 years;No smoking

Exclusion criteria

Exclusion criteria: thyroid disease;No change in levels of LDL patients six weeks after the intervention;Infection; Consumption of any type of supplement (vitamin, mineral, etc.) by the patient in the last 3 months; Acute myocardial infarction in the last 3 months; Cardiac surgery in the last 3 months; Significant kidney failure; Significant liver failure; Unwillingness to cooperate; Antibiotic use during study

Design outcomes

Primary

Measure	Time frame
HOMA-Index. Timepoint: Baseline and End-of-trial. Method of measurement: Formula calculation.	—

Secondary

Measure	Time frame
Fasting plasma glucose. Timepoint: Fasting plasma glucose. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-tria. Method of measurement: Elisa.;QUICKI. Timepoint: Baseline and End-of-tria. Method of measurement: Formula calculation.;Beck Depression Inventory. Timepoint: Baseline and End-of-tria. Method of measurement: Questionnaire.;Nitric oxide (NO). Timepoint: Baseline and End-of-tria. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein (hs-CRP). Timepoint: Baseline and End-of-tria. Method of measurement: Elisa.;Total Antioxidant Capacity (TAC). Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde(MDA). Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Serum Total cholestrol. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Serum LDL-C. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;HDL-C ???. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Serum Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Beck Anxiety Inventory. Timepoint: Baseline and End-of-trial. Method of measurement: Questionnaire.	—

Measure

Time frame

Fasting plasma glucose. Timepoint: Fasting plasma glucose. Method of measurement: Enzymatic.;Insulin. Timepoint: Baseline and End-of-tria. Method of measurement: Elisa.;QUICKI. Timepoint: Baseline and End-of-tria. Method of measurement: Formula calculation.;Beck Depression Inventory. Timepoint: Baseline and End-of-tria. Method of measurement: Questionnaire.;Nitric oxide (NO). Timepoint: Baseline and End-of-tria. Method of measurement: Spectrophotometry.;High sensitivity C-reactive protein (hs-CRP). Timepoint: Baseline and End-of-tria. Method of measurement: Elisa.;Total Antioxidant Capacity (TAC). Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Malondialdehyde(MDA). Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Serum Total cholestrol. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Serum LDL-C. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;HDL-C ???. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Serum Triglyceride. Timepoint: Baseline and End-of-trial. Method of measurement: Laboratory clinical kit.;Beck Anxiety Inventory. Timepoint: Baseline and End-of-trial. Method of measurement: Questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactzahra Hamedifard

Kashan University of Medical Sciences

z.hamedifard.sb@gmail.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 18, 2026